Avillion Has Faith In Merck's Ablynx-Rejected Psoriasis Drug

 
• By Lucie Ellis-Taitt
  
SC1703_Chalkboard Strategy_1200x675
Is Merck's Deal With Avillion A Strategic Portfolio Decision Or Is The Company Distancing Itself From Potential Failure? • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business